Epigenetic Therapy by Phytochemicals in Lung Cancer
Mechanisms, Therapeutic Potential, and Clinical Implications
- 1st Edition - May 1, 2026
- Latest edition
- Editors: Umesh Kumar, Deepak Parashar, Sandeep Kumar Singh, Sachin Kumar
- Language: English
Epigenetic Therapy by Phytochemicals in Lung Cancer provides a comprehensive exploration of the intersection between cancer epigenetics and phytotherapy, focusing on lung cancer… Read more
Epigenetic Therapy by Phytochemicals in Lung Cancer provides a comprehensive exploration of the intersection between cancer epigenetics and phytotherapy, focusing on lung cancer. The book emphasizes the role of epigenetic alterations in cancer progression and presents phytochemicals as promising agents capable of reversing these changes, thereby offering innovative therapeutic strategies. The content examines the mechanisms by which epigenetic modifications, such as DNA methylation and histone modification, contribute to lung cancer. It details specific phytochemicals—like curcumin, resveratrol, and quercetin—and their potential to modulate these pathways, while discussing clinical applications, challenges, and future research directions. For academics, this book equips researchers and healthcare professionals with evidence-based insights into alternative cancer therapies, enhancing understanding of multi-targeted approaches. It serves as a valuable reference for teaching and further research, promoting a more inclusive perspective in cancer care and addressing disparities in treatment access and efficacy.
- Collates current research on epigenetic changes in lung cancer and how specific phytochemicals interact with these mechanisms to halt or reverse tumor progression
- Discusses the therapeutic potential of phytochemicals as low-toxicity alternatives or adjuncts to conventional lung cancer treatments
- Identifies gaps in current research and outlines promising areas for study, helping researchers and practitioners pinpoint future opportunities in developing effective phytochemical-based therapies
researchers, academics and postgraduate students in the fields of oncology, pharmacology, molecular biology, and phytotherapy
Section I: Introduction to Lung Cancer and Epigenetics
1. Lung Cancer: Epidemiology, Pathophysiology, and Current Therapies
2. The Role of Epigenetic Alterations in Lung Cancer Progression
3. Epigenetic Therapy: Overview and Emerging Frontiers
Section II: Phytochemicals as Epigenetic Modulators
4. Introduction to Phytochemicals with Epigenetic Activity
5. DNA Methylation Modulation by Phytochemicals
6. Histone Modification Regulation by Plant-based Compounds
7. Impact of Phytochemicals on Non-coding RNAs in Lung Cancer
Section III: Phytochemicals in Lung Cancer Therapy – Mechanisms and Evidence
8. Polyphenols as Epigenetic Modulators: Curcumin, Resveratrol, and Quercetin
9. Flavonoids and Epigenetic Therapy in Lung Cancer
10. Terpenoids and Their Role in Lung Cancer Epigenetic Modulation
11. Alkaloids and Lung Cancer Epigenetics: Mechanistic Insights and Case Studies
Section IV: Clinical Implications and Future Directions
12. Preclinical and Clinical Trials of Phytochemicals in Lung Cancer Epigenetics: •
13. Insights into clinical trials and real-world applications of phytochemicals
14. Challenges in Phytochemical-based Epigenetic Therapy
15. Formulation and Delivery Systems for Phytochemical-based Epigenetic Drugs
16. Combination Therapies: Phytochemicals with Conventional Lung Cancer Therapies
17. Conclusion and Future Perspectives in Epigenetic Phytotherapy for Lung Cancer
18. Cancer immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors
1. Lung Cancer: Epidemiology, Pathophysiology, and Current Therapies
2. The Role of Epigenetic Alterations in Lung Cancer Progression
3. Epigenetic Therapy: Overview and Emerging Frontiers
Section II: Phytochemicals as Epigenetic Modulators
4. Introduction to Phytochemicals with Epigenetic Activity
5. DNA Methylation Modulation by Phytochemicals
6. Histone Modification Regulation by Plant-based Compounds
7. Impact of Phytochemicals on Non-coding RNAs in Lung Cancer
Section III: Phytochemicals in Lung Cancer Therapy – Mechanisms and Evidence
8. Polyphenols as Epigenetic Modulators: Curcumin, Resveratrol, and Quercetin
9. Flavonoids and Epigenetic Therapy in Lung Cancer
10. Terpenoids and Their Role in Lung Cancer Epigenetic Modulation
11. Alkaloids and Lung Cancer Epigenetics: Mechanistic Insights and Case Studies
Section IV: Clinical Implications and Future Directions
12. Preclinical and Clinical Trials of Phytochemicals in Lung Cancer Epigenetics: •
13. Insights into clinical trials and real-world applications of phytochemicals
14. Challenges in Phytochemical-based Epigenetic Therapy
15. Formulation and Delivery Systems for Phytochemical-based Epigenetic Drugs
16. Combination Therapies: Phytochemicals with Conventional Lung Cancer Therapies
17. Conclusion and Future Perspectives in Epigenetic Phytotherapy for Lung Cancer
18. Cancer immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors
- Edition: 1
- Latest edition
- Published: May 1, 2026
- Language: English
UK
Umesh Kumar
Dr. Umesh Kumar is a Professor in the Department of Biosciences at IMS Ghaziabad (University Courses Campus) and has led the Research Department since 2019. Previously, he served as a Scientific Officer in the Department of Biochemistry at the University of Delhi. He earned his Ph.D. in Biomedical Sciences, focusing on "Epigenetic Regulation in Breast Carcinogenesis," from the Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, in 2013. Dr. Kumar's research interests include molecular diagnosis of cervical cancer, molecular epigenetics of breast carcinogenesis, CAR T-cell therapy, and tumor virology. He has published 50 research articles and contributed over 21 book chapters to reputable publishers. He has received multiple grants and has been honored with two Young Scientist Awards and one Senior Scientist Award. Additionally, he reviews for several international journals and serves as a Doctoral Research Committee (DRC) Expert member at various Indian universities.
Affiliations and expertise
Associate Director Chandigarh University Mohali, PunjabDP
Deepak Parashar
Dr. Deepak Parashar earned his PhD in 2016 from the National Institute of Immunology and Jaipur National University, focusing on the role of SOX4 in cervical cancer. He then joined Dr. Chaluvally’s lab as a postdoctoral fellow at the Medical College of Wisconsin, where he investigated microRNAs like miR551b in breast and ovarian cancers and screened anti-cancer drugs for ovarian treatment. In 2022, he became an Assistant Professor in Dr. Janz’s lab, researching immuno-oncology in multiple myeloma (MM). His current work explores microRNAs and transcription factors like FOXM1 in the tumor immune microenvironment to enhance immunotherapies. Additionally, he studies drug resistance mechanisms and develops nanotechnology-based targeted drug delivery systems for preclinical models. Dr. Parashar has published over 50 manuscripts in prestigious journals and has over 10 years of cancer research experience, mentoring postdocs and graduate students while serving as a peer reviewer and associate editor for various journals.
Affiliations and expertise
Medical College of Wisconsin, USASS
Sandeep Kumar Singh
Dr. Sandeep Kumar Singh holds a PhD in Biotechnology and is an Assistant Professor of Medical Biotechnology at the All India Institute of Medical Sciences (AIIMS), Nagpur, Maharashtra, India. With nearly a decade of research experience, including a postdoctoral tenure in the Department of Neurobiology at The University of Chicago, his expertise spans molecular and cellular neuroscience.
Affiliations and expertise
Department of Medical Biotechnology, All India Institute of Medical Sciences, Nagpur, MH, IndiaSK
Sachin Kumar
Dr. Sachin Kumar is a Scientist in the Department of Medical Oncology at Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi, where he has been serving since 2016. He earned his PhD from AIIMS in 2010, with research focused on circulating DNA and protein markers in lung cancer, and later pursued post-doctoral training in cancer gene therapy at Virginia Commonwealth University, USA.
His current research focuses on liquid biopsy and the role of non-coding RNAs as biomarkers in lung cancer, supported by national and institutional grants. He has authored more than 50 publications in leading international journals and has been recognized with several honors, including the AIIMS Excellence Research Awards (2020, 2022) and the Young Investigator Award from the Indian Society for Study of Lung Cancer (2019).
Dr. Kumar serves on the Editorial Board of Discover Oncology and reviews for numerous high-impact journals. He is also an active member of the American Association for Cancer Research and a Life Member of the Indian Society for Study of Lung Cancer and the Indian Association for Cancer Research.
Affiliations and expertise
Scientist and Head of Division, Biochemical Conversion Division, Sardar Swaran Singh National Institute of Bio-Energy, Kapurthala, India